Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19

• Published in: Medical principles and practice Vol. 34; no. 2; pp. 191 - 200
• Main Authors: Esendagli, Dorina, Sarı, Nuran, Akhan, Sıla, Arslan, Sonay, Doğan Öntaş, İrem Asena, Yılmaz, Gürdal, Aksoy, Firdevs, Kant, Aydın, Yaşar, Kadriye Kart, Ünlü, Esra Canbolat, Akıllı, Işıl Kibar, Çelen, Mustafa Kemal, Mermutluoğlu, Çiğdem, Dayan, Saim, Kara, Emre, Durhan, Gamze, Ünal, Serhat, Demirkol, Barış, Arafat, Levent, Çetinkaya, Erdoğan, Çörtük, Mustafa, Durmuş Koçak, Nagihan, Parmaksız, Elif Torun, İnkaya, Ahmet Çağkan
• Format: Journal Article
• Language: English
• Published: Switzerland S. Karger AG 2025; Karger Publishers
• Subjects: Administration, Inhalation; Adult; Aged; Clinical trials; COVID-19; COVID-19 Drug Treatment; Double-Blind Method; Drug dosages; Dyspnea; Female; Hospitalization; Humans; Infections; Intensive care; Male; Medical imaging; Middle Aged; Patients; Peptides; Performance evaluation; Pneumonia; Prospective Studies; Regulatory approval; Respiratory failure; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Standard of care; Vital signs; COVID-19; SARS-CoV-2; Aviptadil; Inhalation; Lung injury

Objective: We are still in search of new therapeutic options for COVID-19 to prevent new infections, enable fast recovery, and reduce the long-lasting symptoms or sequelae. This study aimed to investigate the short- and long-term effects of inhaled aviptadil on hospitalized, adult COVID-19 patients....